You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis

  • Authors: John Mascarenhas, MD; Jean-Jacques Kiladjian, MD, PhD; Stephen Oh, MD, PhD
  • CME / ABIM MOC / CE Released: 12/30/2022
  • Valid for credit through: 12/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.25 ABIM MOC points

    Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    Pharmacists - 1.25 ACPE Contact Hour(s) (0.125 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists and other healthcare professionals (HCPs) involved in the care of patients with MF.

The goal of this activity is for learners to be better able to understand the challenges in treating cytopenic MF and the new and emerging treatment options to improve patient outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Diagnostic features of cytopenic MF
    • Safety profiles of therapies for cytopenic MF
    • Therapeutic options for patients intolerant to or relapsed after previous Janus kinase (JAK) inhibitors
  • Have greater competence related to
    • Managing treatment-related adverse events (TRAEs) of JAK inhibitors
  • Demonstrate greater confidence in their ability to
    • Tailor treatment options for patients with cytopenic MF


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • John Mascarenhas, MD

    Professor of Medicine
    Tisch Cancer Institute
    Icahn School of Medicine at Mount Sinai
    New York, New York, United States

    Disclosures

    John Mascarenhas, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Bristol Myers Squibb Company; Celgene; Constellation; CTI BioPharma Corp.; Galecto; Geron; Imago; Incyte; Kartos; Karyopharm; Novartis; PharmaEssentia; Roche
    Research funding from: AbbVie; Bristol Myers Squibb Company; Celgene; CTI BioPharma Corp.; Geron; Incyte; Kartos; Merck; Novartis; PharmaEssentia; Roche

Panelists

  • Jean-Jacques Kiladjian, MD, PhD

    Professor of Clinical Pharmacology
    Consultant Hematologist
    Université Paris Cité
    Saint-Louis Hospital
    Paris, France

    Disclosures

    Jean-Jacques Kiladjian, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AOP Orphan; Bristol Myers Squibb Company; Incyte; Novartis; PharmaEssentia

  • Stephen Oh, MD, PhD

    Associate Professor of Medicine
    Division of Hematology
    Washington University School of Medicine
    St Louis, Missouri, United States

    Disclosures

    Stephen Oh, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Blueprint Medicines; Bristol Myers Squibb Company; Constellation; CTI BioPharma Corp.; Disc Medicine; Geron; Incyte; PharmaEssentia; Sierra Oncology

Editor

  • Heather P. Friedman, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.25 contact hour(s) of continuing nursing education for RNs and APNs; 1.00 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number JA0007105-0000-22-419-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis

Authors: John Mascarenhas, MD; Jean-Jacques Kiladjian, MD, PhD; Stephen Oh, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/30/2022

Valid for credit through: 12/30/2023

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand the challenges in treating cytopenic MF and the new and emerging treatment options to improve patient outcomes.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print